ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 528

Assessment of Metacarpal Head Bone Microarchitecture According to Presence or Not of Inflammation in Rheumatoid Arthritis Patients with Low Disease Activity

Shuing Kong1, Hervé Locrelle1, Adamah Amouzougan1, Delphine Denarie1, Philippe Collet1, Béatrice Pallot Prades1, Thierry Thomas1,2 and Hubert Marotte1,2, 1Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, 2INSERM U1059/LBTO, Université de Lyon - Université Jean Monnet, Saint-Etienne, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bone, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Bone alteration at the metacarpeal head during rheumatoid arthritis (RA) disease remained under investigated. High‐resolution peripheral quantitative computed tomography (HRpQCT) allows exploration of microarchitecture of metacarpeal heads during RA. Here, we explored microarchitecture parameters of metacarpeal heads during in RA patients in low disease activity according to persistence or not of local inflammation assessed by US exam.

Methods:  Thirty-three RA patients with erosion on second or third metacarpophalangeal joint were enrolled in this pilot study. All RA patients were treated with bDMARDs for at least 6 months and have low disease activity (DAS28<3.2) since at least 3 months. They were separated in two groups according to local inflammation assessed by US exam on the site of erosion. The group “inactive erosion” was defined by PowerDoppler US (PDUS) ≤ 1 at the metacarpeal joint with erosion, whereas the group “active erosion” was defined by PDUS≥2. Then, HRpQCT of second and third metacarpophalangeal joints was performed. Cortical and trabecular parameters were then assessed and compared in the two groups.

Results:  The main characteristics of the RA population was summarized in the Table. Our RA population shared characteristic of RA patients treated with bDMARDs. Among the 33 RA patients, 21 RA patients were enrolled in the “inactive erosion” group, whereas 12 RA patients were enrolled in the “active erosion” group. No clinical or biological were different in the two groups. Bone volume assessed by BV/TV (%), cortical density (Dcort), and cortical thickness (CTh, μm) were similar in both groups. Trabecular parameters were more heterogeneous. Trabecular density (Dtrab) and trabecular number (TbN, mm-1) were decreased in “active erosion” compared to “inactive erosion” (P<0.001 and <0.02, respectively), whereas trabecular separation (TbSp, μm) and distribution of trabecular separation (TbSpSD, μm) were increased in “active erosion” compared to “inactive erosion” (P=0.049 and 0.032, respectively). Table. RA population characteristics according to local inflammation

Active erosion (n=12) Inactive erosion(n=21) P values
Female , % 69.2 76.2 NS
Age, years, median [range] 69 [47-78] 62 [42-77] NS
MCP2/MCP3 assessed 11/1 18/3 NS
Date of diagnosis, years, median [range] 1996 [1976-2010] 2002 [1977-2012] NS
DAS 28, median [range] 1.87 [0.84-2.85] 2.38 [0.97-3.2] NS
ESR, mm/h, median [range] 6 [2-21] 8 [2-40] NS
CRP, mg/L, median [range] 2 [0-6.6] 1.45 [0-12.5] NS
RF +, % 70 70 NS
ACPA +, % 90 65 NS
Biologics %
TNF blockers 50 71.4
Tocilizumab 41.6 9.5
Abatacept 8.3 19
Biologics duration, years , median [range] 5 [2-11] 6 [2-11] NS
Methotrexate % 58.3 80 NS

Conclusion:  In RA patients in low disease activity treated by bDMARDs, persistence of local joint inflammation is associated with lower bone density at the metacarpal head. Inflammation involved mainly the trabecular compartment. Dtrab parameter was the strongly altered parameter and could be a candidate for prospective study assessing drug effect on periarticular bone damage.


Disclosure: S. Kong, None; H. Locrelle, None; A. Amouzougan, None; D. Denarie, None; P. Collet, None; B. Pallot Prades, None; T. Thomas, None; H. Marotte, None.

To cite this abstract in AMA style:

Kong S, Locrelle H, Amouzougan A, Denarie D, Collet P, Pallot Prades B, Thomas T, Marotte H. Assessment of Metacarpal Head Bone Microarchitecture According to Presence or Not of Inflammation in Rheumatoid Arthritis Patients with Low Disease Activity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessment-of-metacarpal-head-bone-microarchitecture-according-to-presence-or-not-of-inflammation-in-rheumatoid-arthritis-patients-with-low-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-metacarpal-head-bone-microarchitecture-according-to-presence-or-not-of-inflammation-in-rheumatoid-arthritis-patients-with-low-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology